Rosiglitazone (avandia) (DrugBank: Rosiglitazone)
5 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 0 |
| 75 | Cushing disease | 0 |
| 97 | Ulcerative colitis | 0 |
| 222 | Primary nephrotic syndrome | 1 |
| 265 | Lipodystrophy | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00193648 (ClinicalTrials.gov) | July 2005 | 10/9/2005 | Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) | Novel Therapies for Resistant FSGS | Focal Glomerulosclerosis | Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira) | North Shore Long Island Jewish Health System | University of North Carolina;The Cleveland Clinic | Completed | 2 Years | 40 Years | Both | 21 | Phase 1 | United States |